Jazz Pharmaceuticals plc (Ireland) (JAZZ) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, JAZZ scores 47 out of 100, a D grade, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -4.7% and an FCF yield of 9.61%. The cash generation signal is positive, but returns on invested capital are negative, so the cash yield is not translating into value creation on the capital base.
• Whale 13F Flow: 8 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited institutional conviction in the source data.
• Insider Conviction: 13 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the strongest pillar, though still below the midpoint.
• Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.09 and sector sensitivity is noted. The weak score suggests the stock carries amplified exposure to broader market swings without a clear macro tailwind.
• Forensic Balance Sheet: 9 / 20. Per the Roarable RQD rating, the Altman Z-Score is 1.97, the Piotroski F-Score is 7/9, and Debt/Equity is 1. The Piotroski reading is solid, but the Altman reading sits in a range that warrants caution.

For a prospective investor evaluating the stock today, the rating points to a cash-generative business whose accounting profitability, return on capital, and institutional support are all weak. Upside drivers would need to come from a reversal in operating earnings and institutional demand. Valuation tradeoffs are visible: the forward P/E of 36 is elevated relative to negative trailing EPS, so the price already embeds expectations that the reported figures do not yet show.

Per the SEC financials, revenue rose from $3834.2M in FY 2023 to $4267.6M in FY 2025, while operating income swung from positive in FY 2024 to $-430.2M in FY 2025. Per the market data, operating margin is -10.1% and net margin is -8.3%, with gross margin reported as 0%. Per the Roarable RQD rating, the Altman Z-Score is 1.97 and the Piotroski F-Score is 7/9. Debt fell from $6077.6M in FY 2024 to $4328.4M in FY 2025, and cash fell from $2412.9M to $1391.9M over the same period.

Per the recent news feed, one item is listed: a Simply Wall St report titled around Alkermes stock forecasts and analyst predictions, related to JAZZ, flagged YELLOW with a MARKET WIRE impact label, published 1h ago. The summary describes coverage of JAZZ market action, institutional positioning, and fundamental catalysts, but the feed provides no specific catalyst details. Per the Butterfly Supply-Chain Graph, no butterfly links or proprietary signals are present.

• What drove the swing from positive FY 2024 operating income of $716.6M to negative FY 2025 operating income of $-430.2M?
• Why is EPS reported as N/A for every period despite the net income figures provided?
• What explains the drop in cash from $2412.9M to $1391.9M alongside the reduction in debt?
• What is the basis for the forward P/E of 36 when trailing EPS is -5.49?
• Which products and customers generate the reported revenue, and how concentrated are they?